The UK’s cell and gene therapy sector is on the threshold of becoming a global leader in the field. While present challenges include the supply of equipment and skills gaps, Innovation Hubs aim to bridge these through collaboration.

Discover the key strategies and financial nuances of gene therapy like outcome-driven contracts, payment plans, and shared financial agreements

Improving process efficiency is a key approach to factor in when looking at how cell therapy manufacture can be made more sustainable.

Given the widespread incidence of cancers and cardiovascular diseases, having sufficient means to model their behaviour is vital to the development of new treatments. Maintaining tissue contexts in disease modelling is crucial for developing a comprehensive understanding of how different diseases behave.